ANI Other Liab from 2010 to 2025

ANIP Stock  USD 60.19  0.38  0.64%   
ANI Pharmaceuticals Other Liabilities yearly trend continues to be relatively stable with very little volatility. Other Liabilities is likely to grow to about 42.3 M this year. During the period from 2010 to 2025, ANI Pharmaceuticals Other Liabilities destribution of quarterly values had range of 42.3 M from its regression line and mean deviation of  15,575,926. View All Fundamentals
 
Other Liabilities  
First Reported
2014-12-31
Previous Quarter
13.3 M
Current Value
12 M
Quarterly Volatility
13.9 M
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Other Liab Growth Pattern

Below is the plot of the Other Liab of ANI Pharmaceuticals over the last few years. It is ANI Pharmaceuticals' Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

ANI Other Liab Regression Statistics

Arithmetic Mean11,834,765
Geometric Mean1,523,118
Coefficient Of Variation147.97
Mean Deviation15,575,926
Median625,000
Standard Deviation17,511,671
Sample Variance306.7T
Range42.3M
R-Value0.82
Mean Square Error110.2T
R-Squared0.66
Significance0.0001
Slope2,998,571
Total Sum of Squares4599.9T

ANI Other Liab History

202542.3 M
202440.3 M
202235.1 M
202131 M
2020201 K
2019 7000.0

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Other Liab, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Liabilities40.3 M42.3 M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.